title: [Expression of GLUT-1, p63 and DNA-Pkcs in serous ovarian tumors and their significance].
abstract: OBJECTIVE
  To investigate the expression of GLUT1, p63 and DNA-Pkcs in serous ovarian tumors and their significance.
  
  
  METHODS
  GTUL1, p63 and DNA-Pkcs expression at protein level was detected by immunohistochemistry in patients with serous ovarian tumors. Chi-square analysis was used to assess if their expression is associated with clinicopathologic characteristics of the tumors.
  
  
  RESULTS
  Cells in the normal ovarian tissues were not stained with GTUL1 and p63 antiserum, but DNA-Pkcs was positively stained. The intensity of GTUT1 and p63 expression was stronger in malignant ovarian serous tumors compared with other subtypes (P < 0.01). There were significant differences of DNA-PKcs among normal ovaries (100.0%), benign (95.0%), borderline (90.0%) and malignant (60.0%) serious ovarian neoplasms (P < 0.01). The level of GLUT-1 expression was correlated with FIGO staging, intraperitoneal implantation, ascites and lymph node metastasis (P < 0.05). p63 expression was associated with clinicopathologic characteristics except ascites (P < 0.05). DNA-PKcs was only correlated with FIGO staging and lymph node metastasis (P < 0.05).
  
  
  CONCLUSIONS
  The results suggest that the abnormal expression of GTUT1, p63 and DNA-Pkcs may perhaps participate in serous ovarian tumor occurrence and development and may be considered as a marker reflecting tumor malignant behavior.
authors.affiliation: Department of Gynecology, Tumor Hospital of Shanxi Province, Taiyuan 030013, China.
authors.forename: Shu-Li
authors.initials: SL
authors.lastname: Shao
authors.forename: Yu
authors.initials: Y
authors.lastname: Cai
authors.forename: Quan-Hong
authors.initials: QH
authors.lastname: Wang
authors.forename: Li-Juan
authors.initials: LJ
authors.lastname: Yan
authors.forename: Xu-Ye
authors.initials: XY
authors.lastname: Zhao
authors.forename: Li-Xia
authors.initials: LX
authors.lastname: Wang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018284:Cystadenocarcinoma, Serous / Q000378:metabolism* / Q000473:pathology; D018293:Cystadenoma, Serous / Q000378:metabolism / Q000473:pathology; D051747:DNA-Activated Protein Kinase / Q000378:metabolism*; D004848:Epithelium / Q000378:metabolism; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D051272:Glucose Transporter Type 1 / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009367:Neoplasm Staging; D009687:Nuclear Proteins / Q000378:metabolism*; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000473:pathology; D010053:Ovary / Q000166:cytology; D015534:Trans-Activators / Q000378:metabolism*; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins / Q000378:metabolism*; D055815:Young Adult
chemical_list: D051272:Glucose Transporter Type 1; D009687:Nuclear Proteins; C495677:SLC2A1 protein, human; C115051:TP63 protein, human; D015534:Trans-Activators; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins; D051747:DNA-Activated Protein Kinase; C497263:PRKDC protein, human